AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, has announced that it received clearance from the FDA for its AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion system. The AtriClip system is designed to safely and effectively exclude the left atrial appendage. Initial launch in the United States is anticipated to begin later this month with full commercial release planned during the third quarter of 2010.

A recent article in MedCity News raises the question about what will Ohio medical device makers do when the new 2.3 percent sales tax starts in 2013?

In results published in the Annals of Emergency Medicine, a multicenter trial involving University of Cincinnati (UC) research confirms that a new tool can show severe heart attacks in more patients, potentially leading to better diagnoses and faster treatment.

Venture capitalists invested $4.8 billion in 637 deals in the third quarter of 2009, according to the MoneyTree™ Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.